BioXcel Therapeutics Inc (BTAI) financials · rev $642.0K
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
BioXcel Therapeutics Inc (BTAI) rev $642.0K.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $642.0K | $2.27M |
| Cost of Revenue | $164.0K | $2.14M |
| Gross Profit | $478.0K | $123.0K |
| Operating Income | -$50.5M | -$67.2M |
| Net Income | -$69.9M | -$59.6M |
| EPS (Diluted) | -$5.73 | -$23.51 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $44.9M | $38.3M |
| Current Assets | $44.7M | $37.4M |
| Cash & Equivalents | $28.4M | $29.9M |
| Inventory | $722.0K | $679.0K |
| PP&E | $175.0K | $475.0K |
| Total Liabilities | $140.4M | $131.4M |
| Current Liabilities | $53.9M | $22.2M |
| Short-term Debt | $24.9M | N/A |
| Long-term Debt | $84.7M | $102.5M |
| Total Debt | $109.6M† | $102.5M† |
| Shareholders' Equity | -$95.5M | -$93.1M |
| Retained Earnings | -$720.1M | -$650.2M |
† Total Debt: Derived: short-term debt plus long-term debt (no total debt stored).
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Cash Flow | -$57.6M | -$72.0M |
| CapEx | N/A | N/A |
| Investing Cash Flow | N/A | N/A |
| Financing Cash Flow | $56.5M | $36.7M |
| Net Change in Cash | -$1.10M | -$35.4M |
| Free Cash Flow | -$57.6M | -$72.0M |
FAQ
What is BTAI P/E and revenue?
BioXcel Therapeutics Inc (BTAI) rev $642.0K.
What is BTAI revenue?
BioXcel Therapeutics Inc last cached revenue is $642.0K (FY2025).
Is BTAI profitable?
BioXcel Therapeutics Inc last cached net income is -$69.9M (FY2025).
What are BTAI total assets?
BioXcel Therapeutics Inc last cached total assets are $44.9M (FY2025).
What is BTAI free cash flow?
BioXcel Therapeutics Inc last cached free cash flow is -$57.6M (FY2025).
Not investment advice. Cached statements, not a live tape.